Thursday, June 23rd, 2016 - Future Market Insights

Blood cancer is a general term used for the cancers that affect blood, bone marrow or lymphatic system. Most of these cancers start in bone marrow where blood cells (RBC, WBC and platelets) are produced from bone marrow stem cells. In cancerous condition, differentiation of bone marrow stem cells is interrupted to produce abnormal blood cells which hamper the normal functioning of the blood. There are 4 types of blood cancers such as leukemia, Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL) and multiple myeloma. Blood cancers develop due to combination of genetic and environmental factors including but not limited to exposure to ionizing radiation, benzene and other petrochemicals, prior chemotherapy, smoking etc.

Plenty of chemotherapeutic agents are available commercially for the treatment of blood cancer such as Leukeran, Gleevec, Cytarine, Neosar, Oncotrex etc. Several new drugs for blood cancer treatment are in clinical trials such as Panobinostat (Phase 2), Bortezomib (phase 4), Oncofetal Ag (phase 1), Volasertib (phase 2) which are likely to launch in next 5-10 years.

Blood Cancer Treatment Market: Drivers and Restraints

High incidence rate of blood cancers in US (leukemia-13.0, NHL-19.8, HL-2.7, myeloma-6.7 cases per 100,000 population in 2014) is the major driver for the growth of blood cancer treatment market in US.  Advancement in technology, personalized medicine, cost effective treatment procedures are few other factors predicted to keep up the growth of global blood cancer treatment market. However, divergent nature of blood cancers and increasing stringency in the regulatory requirements are some of the major restraints limiting the growth of global blood cancer treatment market.

Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1425

Blood Cancer Treatment Market: Segmentation

The global blood cancer treatment market has been classified on the basis of application, end use and geography.

Based on application, the global blood canner treatment market is divided into following:

  • Biological/immunotherapy

  • Chemotherapy

  • Radiation therapy

  • Targeted therapy

  • Stem cell transplantation

Based on end user type, the global blood canner treatment market is divided into following:

  • Hospitals

  • Clinics

  • Cancer rehabilitation centers

Visit For TOC@  http://www.futuremarketinsights.com/toc/rep-gb-1425

Blood Cancer Treatment Market: Overview

Due of the availability of variety of chemotherapeutic agents for the blood cancer treatment, market for chemotherapeutic agents is expected to hold a greater share in global blood cancer treatment market. Innovative blood cancer treatment procedures are expected to launch into the market in the forecast period. This will also help to increase the market volume. However, expiry of some of the commonly used drugs such as Erbitux (2014), Rituxan (2019), Gleevec (2015), Herceptin (2023) is anticipated to uplift the generic cancer market within the forecast period. Monoclonal antibodies and other immunological treatments are generally known for their lesser side effects and better efficacy. Few biological agents like Peg interferone α-2b and Drotrecogine α are already launched into the US market which are expected to generate the remarkable revenue.

Blood Cancer Treatment Market: Regional Overview

Geographically, the global blood cancer treatment market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa.North America takes the largest share of global blood cancer treatment market followed by Europe. The global blood cancer treatment market is expected to grow in future due to increasing investment by multinational companies in cancer research.

Query Discussion With Analyst@ http://www.futuremarketinsights.com/askus/rep-gb-1425 

Blood Cancer Treatment Market: Key Players

Roche group is one of the leading provider of blood cancer treatment drugs. Some of the key players in blood cancer treatment market are Novartis Pharmaceuticals, Merc & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson Pvt. Ltd., Celgen Corporation, Amgen Inc., Teva pharmaceutical Industries Ltd., Bayer AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd. To name a few.

File Library

Contact Profile

Future Market Insights


Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends.


FMI
P: +1-347-918-3531
W: www.futuremarketinsights.com/

Keywords

Blood Cancer (leukemia, Non-Hodgkin lymphoma, Hodgkin lymphoma, Multiple Myeloma) Treatment Market

Categories

Newsrooms

Sharing

More Formats